Effect of thyrotropin releasing hormone (TRH) on acetylcholine release from different brain areas investigated by microdialysis

Effect of muscarinic receptor modulators in the hypothalamic supraoptic nucleus of the rat

Muscarinic antagonists were injected into the hypothalamic supraoptic nucleus (SON) and their effects on the acetylcholine (ACh) release of this nucleus were studied by in vivo microdialysis techniques. Atropine, AF-DX116 (a M2-receptor antagonist), 4-DAMP (a M3-receptor antagonist) and pirenzepine (a M1-receptor antagonist) concentration-dependently increased the ACh release. The EC50 values for these antagonists were 15 nM for atropine, 7.8 microM for pirenzepine, 0.39 microM for AF-DX116 and 59 nM for 4-DAMP, suggesting the autoregulation of the ACh release through an activation of M2 and M3 subtypes of muscarinic receptors in the SON. The postsynaptic effect of muscarinic receptors on urine outflow was studied by microinjection of selective muscarinic receptor agonists and antagonists into the SON. McN-A-343 (a M1-receptor agonist) had no significant effect on urine outflow. Pre-microinjection of atropine, 4-DAMP, p-F-HHSiD (a M3-receptor antagonist) or pirenzepine into the SON concentration-dependently attenuated the oxotremorine-induced antidiuresis. In contrast, AF-DX116 and methoctramine had no effect on this oxotremorine-induced action. These results suggest that the M3-subtype may contribute to the antidiuretic actions. Nicotine produced an increase in ACh release in the SON and also induced potent antidiuretic effects, both of which were inhibited by hexamethonium. Thus, in the SON, the ACh release may be autoregulated by M2- and M3-subtypes of muscarinic receptors and the antidiuretic effects of ACh produced through an activation of the M3-subtype.

Glutamatergic regulation of acetylcholine output in different brain regions: a microdialysis study in the rat

The glutamatergic regulation of cortical and striatal cholinergic neurons was investigated by measuring ACh output from the parietal cortex and striata of freely moving rats after administration of the competitive NMDA-receptor antagonist 3-((RS)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP). It has been shown that intracerebroventricular administration of 5 nmol of CPP brings about a long lasting 100% increase in ACh output from the parietal cortex but does not affect ACh output from the striatum. Conversely, local perfusion of the striata with 50 microM CPP results in a 45% decrease in ACh output from the striatum but has no effect on parietal ACh output. The decrease in striatal ACh output induced by CPP is antagonized by concurrent perfusion with NMDA. In conclusion, glutamate may exert both inhibitory and excitatory modulatory effects on ACh output, through NMDA receptors, according to the neuronal circuitry existing in different brain regions.

A novel approach for studying septo-hippocampal cholinergic neurons in freely moving rats: a microdialysis study with dual-probe design

In this study, the overflow of acetylcholine (ACh) in the septo-hippocampal system was studied using intracerebral microdialysis in freely moving rats. Dialysis probes were implanted in the ventral hippocampus and in the medial septal area (MS), including a part of the ventral limb of the diagonal band of Broca (VDB). Dialysis samples were analysed 'on-line' using HPLC with post column enzymatic conversion and electrochemical detection. Local perfusion of 1 mumol/l of the sodium-channel blocker tetrodotoxin (TTX) through the probe resulted in 94% and 92% decrease in extracellular levels of ACh in the hippocampus and the septal area, respectively. The effects of septal manipulation on the efflux of ACh in the hippocampus were studied by electrical stimulation of the septal area and by administering drugs via the septal probe. Electrical stimulation of the MS/VDB caused a 336% increase in the output of ACh in the hippocampus. Perfusion of 3 mumol/l TTX through the septal probe caused a maximal decrease of 56% in the output of ACh in the ventral hippocampus. When perfused in the MS/VDB, the excitatory amino-acid agonists N-methyl-D-aspartate (NMDA) (100 mumol/l) and kainic acid (10 mumol/l) caused an increase in the extracellular level of ACh in the hippocampus by 83% and 161%, respectively. Thus, the overflow of ACh in the hippocampus and the septal area both depend on neuronal impulse flow. The extracellular level of ACh in the hippocampus is at least partially dependent on impulse flow in septo-hippocampal fibres. Moreover, the output of ACh in the hippocampus can be manipulated by electrical and pharmacological stimulation of the MS/VDB.

In vivo regulation of extracellular adenosine levels in the cerebral cortex by NMDA and muscarinic receptors

The adenosine concentration in samples of perfusate was determined 24 h after implantation of microdialysis fibre in the cortex. High performance liquid chromatography coupled with a fluorometric detector was used. K+ (100 mM) depolarization was followed by a 2- to 4-fold increase in adenosine efflux. The addition of tetrodotoxin (1 microM) to the perfusate was followed by a decrease in spontaneous and K(+)-evoked adenosine efflux. The increase induced by high K+ was markedly inhibited by the NMDA receptor antagonist, D(-)-2-amino-7-phosphonoheptanoic acid (1 mM, D-AP7), but not by the muscarinic receptor antagonist, atropine (1.5 microM). The acetylcholine esterase inhibitor, physostigmine (7 microM), and the muscarinic receptor agonist, oxotremorine (100 microM), significantly enhanced the K(+)-evoked increase in adenosine. The spontaneous efflux of adenosine was not modified by any of the drugs tested. A neurotoxic lesion of the cholinergic pathway innervating the cortex, although inducing a marked decrease in cortical choline acetyltransferase activity, did not significantly modify the cortical adenosine efflux. It is concluded that, under K(+)-depolarizing conditions, adenosine efflux is triggered by excitatory amino acids and enhanced by muscarinic activation.

Nefiracetam enhances acetylcholine outflow from the frontal cortex: in vivo microdialysis study in the rat

The effects of nefiracetam [DM-9384; N-(2, 6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide], a cognitive enhancer, on extracellular acetylcholine and glutamic acid in the frontal cortex were studied using brain microdialysis in freely moving rats. Nefiracetam administration (1 mg/kg, p.o.) doubled the amount of acetylcholine in the dialysate. When tetrodotoxin was added to the perfusion solution, the basal level of acetylcholine decreased and nefiracetam caused no increase in acetylcholine outflow. The amount of glutamic acid in the dialysates was not affected by nefiracetam. These results suggest that nefiracetam increases the amount of acetylcholine within the cholinergic synaptic clefts.

Behavioural effects of scopolamine and the TRH analogue RX77368 on radial arm maze performance in the rat

Effects of repeated intracerebroventricular administration of the thyrotrophin-releasing hormone (TRH) analogue, RX77368 (3,3'-dimethyl-TRH, 2 μg, once daily), on a scopolamine-induced performance deficit in an eight-arm radial maze were evaluated in adult rats. Scopolamine (0.3 mg/kg i.p.-30 min) pre-treatment produced a significant deficit in the number of unrepeated arm entries and total arm entries and increased the percentage of incorrect arm entries and the total time on the maze, compared with saline-treated controls. Prior treatment with RX77368 (40 min before maze testing) produced a partial but significant attenuation of the scopolamine-induced performance deficit on the maze during the first five trials but RX77368 also enhanced maze performance during the same period when given alone. These results suggest that the observed scopolamine-induced performance deficit on the radial arm maze partly results from a reduction in locomotion and maze exploration rather than solely impairment of memory, and that RX77368 treatment may improve radial maze performance by increasing arousal and exploratory behaviour in rats rather than directly enhancing cognition.

Potassium currents operated by thyrotrophin-releasing hormone in dissociated CA1 pyramidal neurones of rat hippocampus

1. Membrane currents activated by thyrotrophin-releasing hormone (TRH) were investigated in the dissociated rat hippocampal CA1 pyramidal neurone using the nystatin perforated patch recording configuration. 2. Under current-clamp condition, TRH caused a transient hyperpolarization accompanied by a decrease of firing activity and a successive long-lasting depolarization. The latter induced a blockade of firing. 3. When neurones were held at a holding potential (VH) of -40 mV under voltage clamp, TRH elicited a transient outward current with an increase in the membrane conductance, which was followed by a sustained inward current with a decrease in membrane conductance. The inactive TRH metabolite, TRH free acid, did not induce any currents. 4. The reversal potential of TRH-induced outward current (ETRH) was close to the K+ equilibrium potential (EK). The change in ETRH for a 10-fold change in extracellular K+ concentration was 56.4 mV, indicating that the membrane behaves like a K+ electrode in the presence of TRH. On the other hand, the TRH-induced inward current was due to suppression of a slow inward current relaxation during hyperpolarizing voltage commands to -50 mV from a VH of -40 mV, indicating the suppression of the voltage- and time-dependent component of the K+ current (M-current). 5. The TRH-induced outward current (ITRH) increased in a concentration-dependent manner over the concentration range 10(-8)-10(-6) M. The half-maximum concentration was 7.4 x 10(-8) M and the Hill coefficient was 1.5. 6. The TRH-induced outward current (ITRH) was antagonized by K+ channel blockers such as tetraethylammonium (TEA), 4-aminopyridine (4-AP) and Ba2+ in a concentration-dependent manner. ITRH was insensitive to both apamin and iberiotoxin. 7. The first application of TRH to neurones perfused with Ca(2+)-free external solution containing 2 mM EGTA could induce ITRH but the TRH response diminished dramatically with successive applications. Intracellular perfusion with a Ca2+ chelator, 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), also diminished the TRH response. 8. The depletion of Ca2+ from the intracellular Ca2+ store by thapsigargin blocked the TRH response without affecting the caffeine response. Pretreatment with Li+ significantly enhanced ITRH, suggesting that ITRH is involved in the elevation of intracellular free Ca2+ released from the inositol 1,4,5-trisphosphate (IP3)-sensitive Ca2+ store site but not from the caffeine-sensitive one. 9. Staurosporine, a protein kinase C (PKC) inhibitor, suppressed ITRH in a concentration-dependent manner (the half-maximum inhibitory concentration (IC50), was 2.45 x 10(-8) M).(ABSTRACT TRUNCATED AT 400 WORDS)

Daily changes in the release of acetylcholine from rat primary somatosensory cortex

Using microdialysis, acetylcholine (ACh) release was measured in the somatosensory cortex of 14 rats over a 24-h period. The release of ACh was 0.195 pmol/min during the day and 0.344 pmol/min at night. The length of exposed dialysis membrane within the cortex was an important source of variability in the absolute amounts of ACh collected. Even after rejecting some cases where the membrane contacted only the superficial cortical layers, this factor accounted for 25% of the variation of absolute amounts collected in different animals. After correcting for the length of exposed membrane, the release of ACh was shown to increase 52% at night during the time when the animals were awake, feeding and grooming. Variability in the measures of ACh release obtained during periods of activity was greater than its variability during periods of inactivity. These data were interpreted in the context of several hypothesized roles for ACh in sensory cortex.

Galanin fails to alter both acquisition of a two trial per day water maze task and neurochemical markers of cholinergic or serotonergic neurones in adult rats

The co-existence of galanin with acetylcholine in ventral forebrain neurones combined with evidence that galanin attenuates cholinergic function and is present in senile plaques in Alzheimer's disease all implicate this neuropeptide in the regulation of cognition. This study simultaneously examines the effect of galanin on acquisition in a Morris water maze and post-training markers of cholinergic and serotonergic forebrain neurones thought to be involved in cognition. Synthetic porcine galanin (10(-9) to 10(-6) M) produced dose-related inhibition of atropine sensitive indirectly-evoked contractions of an isolated guinea-pig ileum which was unaffected by naloxone (10(-7) M). This confirmed the bioactivity of synthetic galanin, which reduces acetylcholine, but not opiate, release from the ileal myenteric plexus. Galanin pretreatment (1 or 10 micrograms i.c.v., -15 min) failed to alter acquisition of a Morris water maze task (2 trials per day) in Hooded Lister rats. Following behavioural acquisition, five days of galanin administration did not alter choline acetyltransferase activity, thyrotrophin-releasing hormone-like immunoreactivity or 5-hydroxytryptamine levels or turnover in the frontal cortex, hippocampus or septum, although dopamine levels were significantly elevated in the frontal cortex. These findings suggest that galanin does not affect acquisition in a simple visual-spatial task which taxes reference more than working memory and questions the assumption that a cholinergic mechanism is the major contributor to previously reported cognitive effects of galanin.

Low-dose thyrotropin-releasing hormone effects in cognitively impaired alcoholics

The cognitive effects of a low dose of thyrotropin-releasing hormone (TRH) (2.0 mg, IV) were evaluated in 18 chronic alcoholic patients who exhibited memory dysfunction secondary to chronic alcohol abuse. The study used a double-blind crossover design that compared cognitive functions in patients with 2.0 mg of TRH IV as compared with a placebo. TRH was chosen because of its ability to enhance cholinergic transmission. Only minimal effects were seen with TRH. Patients with a shorter duration of alcohol use (mean of 16 years) performed significantly better with TRH as compared with placebo on a test involving verbal learning and memory. Those with a more chronic history of alcohol abuse (mean of 27 years) did not show such a response. All of the subjects showed cardiovascular response to TRH. Factors that may have contributed to the results of our study are discussed. It is our impression that future studies evaluating the cognitive effects of TRH in chronic alcoholics need to include an evaluation of the functional activity of TRH in the brain.

Effect of K+ depolarization, tetrodotoxin, and NMDA receptor inhibition on extracellular adenosine levels in rat striatum

Extracellular adenosine in the striatum of adult male rats was measured by the use of a microdialysis fibre inserted transversely in the striatum. The adenosine concentration in samples of perfusate was determined by HPLC coupled to U.V. detection. The adenosine concentration (corrected for recovery) decreased after implantation of the probe. Two hours later it was 1.83 +/- 0.22 in anaesthetized rats, whereas it was 40% higher in rats in which anaesthesia had been discontinued. Twenty-four hours later the adenosine concentration was 0.124 +/- 0.09 microM; the addition of dipyridamole (100 microM), an adenosine uptake blocker, to the perfusate resulted in a 76% increase in adenosine concentration in the effluent, whereas addition of the adenosine deaminase inhibitor erythro-2-(hydroxy-3-nonyl) adenine (100 microM) caused a 260% increase. The addition of tetrodotoxin (1 microM) was followed by a decrease in basal adenosine concentration and a partial inhibition of the increase in adenosine evoked by K+ depolarization. The increase induced by high K+ was markedly inhibited by the NMDA receptor antagonist D(-)-amino-7-phosphoeptanoic acid (1 mM, D-AP7). These findings indicate that the extracellular adenosine level is influenced by neuronal activity, and that under strong depolarizing conditions the increase in adenosine level involves NMDA receptor activation.

Effects of a novel thyrotropin-releasing hormone analogue, JTP-2942, on extracellular acetylcholine and choline levels in the rat frontal cortex and hippocampus

The effects of a novel thyrotropin-releasing hormone (TRH) analogue, N alpha-[(1S,2R)-2-methyl-4-oxocyclopentanecarbonyl]-L-histidyl-L-pr olinamide (JTP-2942) on acetylcholine (ACh) release and on the extracellular choline level were investigated in rat frontal cortex and hippocampus by microdialysis, and were compared with effects of TRH. JTP-2942 (0.3 mg/kg i.p.) produced a marked (> 300%) and persistent increase of ACh release in both the frontal cortex and hippocampus, while TRH (3 mg/kg i.p.) caused a significant but transient increase of ACh to about 200% in the frontal cortex. Both drugs significantly decreased the choline levels in both brain regions. Investigation of the effects of JTP-2942 (0.001-1 mM) and TRH (1 and 10 mM) on ACh release and choline levels when perfused through the dialysis probe revealed that JTP-2942 had a greater effect than TRH in both the frontal cortex and the hippocampus. The action of JTP-2942 was about 1000-fold more potent than that of TRH in both brain regions. Oral administration of JTP-2942 at a dose of 10 mg/kg markedly and persistently increased the release of ACh and at doses of 1-10 mg/kg decreased the extracellular choline level in the frontal cortex and hippocampus. These results also suggest that JTP-2942 has some selectivity for the hippocampus compared to the frontal cortex after both systemic administration and local injection. The increase of ACh release caused by JTP-2942 was completely antagonized by perfusion with tetrodotoxin (TTX, 1 microM), suggesting that the action of JTP-2942 on cholinergic neurons was mediated via neuronal activity.

Regulation of spontaneous acetylcholine release in the hypothalamic vasopressinergic supraoptic nucleus of a freely moving rat: a study by in vivo microdialysis

We employed a brain microdialysis method to examine the possible regulation of spontaneous acetylcholine (ACh) release in the hypothalamic vasopressinergic supraoptic nucleus (SON) of rats. We monitored the basal ACh release in the SON-microdialysate. The addition of tetrodotoxin (10(-6) M) to the perfusate (saline containing 10(-4) M physostigmine) decreased the basal ACh release. A muscarinic receptor antagonist, atropine (non-selective) or pirenzepine (M1-selective), increased the basal ACh release in a concentration-dependent manner. The maximal increase occurred at 20-40 min after the start of the infusion of antagonists. The ED50 values for the stimulatory effects of atropine and pirenzepine were 9.4 x 10(-8) and approx. 10(-4) M, respectively. The effect of atropine (10(-6) M) was inhibited by simultaneous addition of the muscarinic agonist oxotremorine (10(-5) M). The results showed a negative feedback regulation of the spontaneous ACh release through the activation of muscarinic receptors in the SON. The weak effect of pirenzepine in increasing the ACh release, compared with atropine, suggests that ACh release in the nucleus is mainly regulated by the non-M1-muscarinic receptor subtype.

Age-dependent modulation of in vivo cortical acetylcholine release by benzodiazepine receptor ligands

In vivo microdialysis was utilized to determine the effects of benzodiazepine receptor (BZR) ligands on cortical acetylcholine (ACh) release in awake young and aged rats. There were no significant differences in baseline cortical ACh release as a function of age. While administration of the BZR selective inverse agonist ZK 93 426 increased ACh release in both groups of animals, the aged rats exhibited a greater stimulation. Unexpectedly, under the present testing conditions, the BZR agonist chlordiazepoxide (CDP) had no systematic effect on ACh release in either group. The presence or absence of these drug effects or drug-age interactions was not secondary to the impact of these compounds on behavioral activity. Cortical ACh release could also be stimulated by turning off the lights in the observation room or by the systemic administration of scopolamine. Aged rats were at least as able as their younger counterparts to respond to these manipulations with increased release. These results suggest that basal and stimulated release of cortical ACh is not impaired at the ages studied. Moreover, selective inverse BZR agonists may be a potent way of trans-synaptically stimulating cortical cholinergic transmission.

Regulation of regional cerebral blood flow by cholinergic fibers originating in the basal forebrain

We review mainly recent studies on vasodilative regulation of cortex and hippocampus by central cholinergic nerves originating in the basal forebrain. We also briefly review the influence of other central noradrenergic fibers originating in the locus ceruleus, serotonergic fibers originating in the dorsal raphe nucleus, dopaminergic fibers originating in the substantia nigra, and peripheral sympathetic and parasympathetic nerve fibers upon regulation of regional cerebral blood flow. Local metabolites have long been considered to play an important physiological role in regulating regional cerebral blood flow. However, the evidence reviewed here emphasizes that the regulation of regional cerebral blood flow by these central cholinergic nerves is independent of regional metabolism. We propose through this review that although studies investigating neural regulation of cortical and hippocampal blood flow by cholinergic fibers originating in the basal forebrain have added much to the understanding of regulation of regional cerebral blood flow further studies are needed to determine the physiological relevance of regional cerebral blood flow in relation to higher nervous functions such as memory, learning, and personality, and changes in these cognitive functions with aging and pathology such as Alzheimer's disease.

Responses of regional cerebral blood flow to intravenous administration of thyrotropin releasing hormone in aged rats

The effects of i.v. administration of thyrotropin releasing hormone (TRH) on regional cerebral blood flow (rCBF) were examined in both healthy adult (3-5 months old) and healthy aged (24-25 months old) male Wistar rats under halothane anesthesia. The rCBFs in 9 different brain regions-cerebral cortex, caudate putamen, hippocampus, thalamus + hypothalamus, superior colliculus, inferior colliculus, cerebellum, pons, and medulla-were measured by [14C]iodoantipyrine method. In the adult rats, i.v. administration of TRH (300 micrograms/kg) produced significant increases in rCBFs in cerebral cortex, caudate putamen, hippocampus, thalamus + hypothalamus and superior colliculus. In the aged rats, the rCBFs in all brain regions measured did not change significantly by TRH administration. From these results, it is suggested that the system involved in TRH-induced vasodilatation of cerebral blood vessels was impaired with aging.

Y-29794--a non-peptide prolyl endopeptidase inhibitor that can penetrate into the brain

A novel non-peptide prolyl endopeptidase (PPCE) inhibitor, Y-29794, has been identified. Y-29794 selectively and competitively inhibited rat brain PPCE (Ki = 0.95 nM) in a reversible manner. Ex vivo study demonstrated that Y-29794 could penetrate into brain to exhibit dose-dependent and long-lasting inhibition. Furthermore, Y-29794 was found to potentiate the effect of TRH on the release of ACh in the rat hippocampus. These results indicate that Y-29794 is an orally active, potent and specific PPCE inhibitor and should be of value in studies on the physiological role of the enzyme in neuropeptide metabolism especially in memory process.

TRH protection against memory retrieval deficits is independent of endocrine effects

An electrobrainshock (EBS)-induced memory retrieval deficit was produced in normal and hypophysectomized mice. In normal mice, thyrotropin-releasing hormone (TRH) (0.1 to 30 mg/kg) protected against this EBS disruption of memory after intraperitoneal but not oral (1.0 to 100 mg/kg) administration. In hypophysectomized mice, TRH (0.3 and 3.0 mg/kg) also protected against the retrieval deficit induced by EBS. The memory protection afforded by TRH was unrelated to its ability to elevate plasma levels of triiodothyronine (T3) and thyroxine (T4), nor was TRH's memory protection mediated through an anticonvulsive mechanism. These results support the notion that TRH may play an important role in memory modulation and may have therapeutic value in certain disease states in humans.